High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7.

The Swedish National Board of Health and Welfare rejects prioritising andrology as a speciality

Male infertility can be linked to a shorter lifespan and several severe diseases, but when couples who want children are examined, the focus is on the woman. Ex...

Lonza

ProPharma

SGS Fimko Ltd.

Fundamental Aspects of Airy Disk Patterns

Knowledge Article from ZEISS.

Lucy Robertshaw: Are we in the perfect storm?

“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of ...

QPS Netherlands B.V

RegSmart Life Science AB

Wusson Accelerator AB

Microscopy in Urinalysis: Observe Urine, Detect Abnormalities

Webinar on 18th March 2025, 10 AM - 11 AM CET.

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Truly Labs AB

Marie Gårdmark: New incentives for orphan products on its way

"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”

When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, abou...

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

Sweden is organising a large life science conference as part of the EU presidency

On 26-27 June, Sweden will host a European meeting on life science.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.